NCT06394570View on ClinicalTrials.gov

Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions

Bladder Cancer

Interventions

DRUG

Enfortumab vedotin

Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles

Trial Locations (1)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT06394570 - Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter